Stats

Preregistered note1253 before data retrieval. Nine sector ETFs; rank prior 3 session adjusted close returns at weekly boundary, buy worst nextopen if its own return negative. SPY subtraction does not change cross-sectional ranks. Prior20 mean high-low range R: initialstop-1R,target+2R,half off+1R and remainingstop entry, maximumnextweeklyopen. Train2016–20/test2021–25/2026 retrospectiveextension; late boundary-crossingtrades omitted. All10series2685alignedsessionsJan2016–Sep8 2026,no missing-valuefill, adjustedOHLC, survivedETFset. Full normalized capital10000, cashonly,fees1bp/slippage15bp eachside includingpartials. Customevent cash and every equitypoint verified by vectorbt from_orders; exactfinal5139.891293176538. Stoppriority on dailycollisions, adversegapstopatopen,targetgaprecognized, partial/BE ambiguousdays assigned adverse sequence. Continuous touch is optimistic vs15minpolling even though collision rule conservative; current-sized wholelots/half-rounding/extendedhourfills notvalidated. Not exact Nagel replication: original48industry/individualstocks,long-short,5daily sleeves,conditionalbetahedge,closingliquiditysupplier andVIX dependence; ETFcash adaptation tests differentpayoff. Premises1.recordedreturns from fixedrule;2.basepositiveedge must survive costs/uncertainty;3.wholefamilyfailsstressandCI. Conclusion research-only/noallocation. Sample 225,p0.52,W1.350008917560452%,L2.035598201882041%,mean-0.2750824997719447%; years{"2021":-19.77584279508666,"2022":-16.816823077388243,"2023":4.845641283599722,"2024":-18.778632296479834,"2025":-9.553328538558715};exitcounts{"stop":123,"time":39,"breakeven":35,"target":24,"target_gap":4}. Trade samplecounts completed roundtrips,partiallegs aggregated. Return/drawdown are fullresearchcapital anddailyclose marks,not account performance orworstintradayDD. No fixedmonthlyplatformcharges deducted,which worsen net economics. Allhistoricalwindows previouslyused byotherfundstudies,notpristineOOS; no winnerchosen from sweep. Sources https://www.nber.org/system/files/working_papers/w17653/w17653.pdf ; https://runway.adityaperswal.workers.dev/data/stock-bars?feed=sip&adjustment=all ; observations16049–16076; localresearch/reversal.py.

Preregistered note1253 before data retrieval. Nine sector ETFs; rank prior 3 session adjusted close returns at weekly boundary, buy worst nextopen if its own return negative. SPY subtraction does not change cross-sectional ranks. Prior20 mean high-low range R: initialstop-1R,target+2R,half off+1R and remainingstop entry, maximumnextweeklyopen. Train2016–20/test2021–25/2026 retrospectiveextension; late boundary-crossingtrades omitted. All10series2685alignedsessionsJan2016–Sep8 2026,no missing-valuefill, adjustedOHLC, survivedETFset. Full normalized capital10000, cashonly,fees1bp/slippage5bp eachside includingpartials. Customevent cash and every equitypoint verified by vectorbt from_orders; exactfinal8060.95807690537. Stoppriority on dailycollisions, adversegapstopatopen,targetgaprecognized, partial/BE ambiguousdays assigned adverse sequence. Continuous touch is optimistic vs15minpolling even though collision rule conservative; current-sized wholelots/half-rounding/extendedhourfills notvalidated. Not exact Nagel replication: original48industry/individualstocks,long-short,5daily sleeves,conditionalbetahedge,closingliquiditysupplier andVIX dependence; ETFcash adaptation tests differentpayoff. Premises1.recordedreturns from fixedrule;2.basepositiveedge must survive costs/uncertainty;3.wholefamilyfailsstressandCI. Conclusion research-only/noallocation. Sample 225,p0.52,W1.552911990645975%,L1.8394731261162218%,mean-0.07543286539987953%; years{"2021":-12.571197649678457,"2022":-9.164950188317588,"2023":14.719415636254652,"2024":-10.951740773413865,"2025":-0.6389174619807036};exitcounts{"stop":123,"time":39,"breakeven":35,"target":24,"target_gap":4}. Trade samplecounts completed roundtrips,partiallegs aggregated. Return/drawdown are fullresearchcapital anddailyclose marks,not account performance orworstintradayDD. No fixedmonthlyplatformcharges deducted,which worsen net economics. Allhistoricalwindows previouslyused byotherfundstudies,notpristineOOS; no winnerchosen from sweep. Sources https://www.nber.org/system/files/working_papers/w17653/w17653.pdf ; https://runway.adityaperswal.workers.dev/data/stock-bars?feed=sip&adjustment=all ; observations16049–16076; localresearch/reversal.py.

Preregistered note1253 before data retrieval. Nine sector ETFs; rank prior 3 session adjusted close returns at weekly boundary, buy worst nextopen if its own return negative. SPY subtraction does not change cross-sectional ranks. Prior20 mean high-low range R: initialstop-1R,target+1.5R,half off+1R and remainingstop entry, maximumnextweeklyopen. Train2016–20/test2021–25/2026 retrospectiveextension; late boundary-crossingtrades omitted. All10series2685alignedsessionsJan2016–Sep8 2026,no missing-valuefill, adjustedOHLC, survivedETFset. Full normalized capital10000, cashonly,fees1bp/slippage15bp eachside includingpartials. Customevent cash and every equitypoint verified by vectorbt from_orders; exactfinal5418.042992912734. Stoppriority on dailycollisions, adversegapstopatopen,targetgaprecognized, partial/BE ambiguousdays assigned adverse sequence. Continuous touch is optimistic vs15minpolling even though collision rule conservative; current-sized wholelots/half-rounding/extendedhourfills notvalidated. Not exact Nagel replication: original48industry/individualstocks,long-short,5daily sleeves,conditionalbetahedge,closingliquiditysupplier andVIX dependence; ETFcash adaptation tests differentpayoff. Premises1.recordedreturns from fixedrule;2.basepositiveedge must survive costs/uncertainty;3.wholefamilyfailsstressandCI. Conclusion research-only/noallocation. Sample 225,p0.52,W1.3941282054574626%,L2.035598201882043%,mean-0.25214047006550006%; years{"2021":-21.661419014315452,"2022":-14.01779110571465,"2023":6.137142136057849,"2024":-18.073610246089235,"2025":-7.494630644957379};exitcounts{"stop":114,"target":39,"breakeven":35,"time":26,"target_gap":11}. Trade samplecounts completed roundtrips,partiallegs aggregated. Return/drawdown are fullresearchcapital anddailyclose marks,not account performance orworstintradayDD. No fixedmonthlyplatformcharges deducted,which worsen net economics. Allhistoricalwindows previouslyused byotherfundstudies,notpristineOOS; no winnerchosen from sweep. Sources https://www.nber.org/system/files/working_papers/w17653/w17653.pdf ; https://runway.adityaperswal.workers.dev/data/stock-bars?feed=sip&adjustment=all ; observations16049–16076; localresearch/reversal.py.

Preregistered note1253 before data retrieval. Nine sector ETFs; rank prior 3 session adjusted close returns at weekly boundary, buy worst nextopen if its own return negative. SPY subtraction does not change cross-sectional ranks. Prior20 mean high-low range R: initialstop-1R,target+1.5R,half off+1R and remainingstop entry, maximumnextweeklyopen. Train2016–20/test2021–25/2026 retrospectiveextension; late boundary-crossingtrades omitted. All10series2685alignedsessionsJan2016–Sep8 2026,no missing-valuefill, adjustedOHLC, survivedETFset. Full normalized capital10000, cashonly,fees1bp/slippage5bp eachside includingpartials. Customevent cash and every equitypoint verified by vectorbt from_orders; exactfinal8497.18698967831. Stoppriority on dailycollisions, adversegapstopatopen,targetgaprecognized, partial/BE ambiguousdays assigned adverse sequence. Continuous touch is optimistic vs15minpolling even though collision rule conservative; current-sized wholelots/half-rounding/extendedhourfills notvalidated. Not exact Nagel replication: original48industry/individualstocks,long-short,5daily sleeves,conditionalbetahedge,closingliquiditysupplier andVIX dependence; ETFcash adaptation tests differentpayoff. Premises1.recordedreturns from fixedrule;2.basepositiveedge must survive costs/uncertainty;3.wholefamilyfailsstressandCI. Conclusion research-only/noallocation. Sample 225,p0.52,W1.597119605511995%,L1.8394731261162252%,mean-0.05244490566955085%; years{"2021":-14.626110737345076,"2022":-6.108440230685142,"2023":16.132542794177795,"2024":-10.178779321536025,"2025":1.622685403241042};exitcounts{"stop":114,"target":39,"breakeven":35,"time":26,"target_gap":11}. Trade samplecounts completed roundtrips,partiallegs aggregated. Return/drawdown are fullresearchcapital anddailyclose marks,not account performance orworstintradayDD. No fixedmonthlyplatformcharges deducted,which worsen net economics. Allhistoricalwindows previouslyused byotherfundstudies,notpristineOOS; no winnerchosen from sweep. Sources https://www.nber.org/system/files/working_papers/w17653/w17653.pdf ; https://runway.adityaperswal.workers.dev/data/stock-bars?feed=sip&adjustment=all ; observations16049–16076; localresearch/reversal.py.

Preregistered note1253 before data retrieval. Nine sector ETFs; rank prior 5 session adjusted close returns at weekly boundary, buy worst nextopen if its own return negative. SPY subtraction does not change cross-sectional ranks. Prior20 mean high-low range R: initialstop-1R,target+1.5R,half off+1R and remainingstop entry, maximumnextweeklyopen. Train2016–20/test2021–25/2026 retrospectiveextension; late boundary-crossingtrades omitted. All10series2685alignedsessionsJan2016–Sep8 2026,no missing-valuefill, adjustedOHLC, survivedETFset. Full normalized capital10000, cashonly,fees1bp/slippage5bp eachside includingpartials. Customevent cash and every equitypoint verified by vectorbt from_orders; exactfinal11078.92489715759. Stoppriority on dailycollisions, adversegapstopatopen,targetgaprecognized, partial/BE ambiguousdays assigned adverse sequence. Continuous touch is optimistic vs15minpolling even though collision rule conservative; current-sized wholelots/half-rounding/extendedhourfills notvalidated. Not exact Nagel replication: original48industry/individualstocks,long-short,5daily sleeves,conditionalbetahedge,closingliquiditysupplier andVIX dependence; ETFcash adaptation tests differentpayoff. Premises1.recordedreturns from fixedrule;2.basepositiveedge must survive costs/uncertainty;3.wholefamilyfailsstressandCI. Conclusion research-only/noallocation. Sample 35,p0.6857142857142857,W1.3326076064494985%,L1.9265552735026028%,mean0.30829927275026664%; years{"2026":10.789248971576026};exitcounts{"stop":14,"breakeven":9,"target":8,"time":3,"target_gap":1}. Trade samplecounts completed roundtrips,partiallegs aggregated. Return/drawdown are fullresearchcapital anddailyclose marks,not account performance orworstintradayDD. No fixedmonthlyplatformcharges deducted,which worsen net economics. Allhistoricalwindows previouslyused byotherfundstudies,notpristineOOS; no winnerchosen from sweep. Sources https://www.nber.org/system/files/working_papers/w17653/w17653.pdf ; https://runway.adityaperswal.workers.dev/data/stock-bars?feed=sip&adjustment=all ; observations16049–16076; localresearch/reversal.py.

Preregistered note1253 before data retrieval. Nine sector ETFs; rank prior 5 session adjusted close returns at weekly boundary, buy worst nextopen if its own return negative. SPY subtraction does not change cross-sectional ranks. Parent exits nextweeklyopen without protectiveexits, not venueeligible. Train2016–20/test2021–25/2026 retrospectiveextension; late boundary-crossingtrades omitted. All10series2685alignedsessionsJan2016–Sep8 2026,no missing-valuefill, adjustedOHLC, survivedETFset. Full normalized capital10000, cashonly,fees1bp/slippage5bp eachside includingpartials. Customevent cash and every equitypoint verified by vectorbt from_orders; exactfinal13996.983495286033. Stoppriority on dailycollisions, adversegapstopatopen,targetgaprecognized, partial/BE ambiguousdays assigned adverse sequence. Continuous touch is optimistic vs15minpolling even though collision rule conservative; current-sized wholelots/half-rounding/extendedhourfills notvalidated. Not exact Nagel replication: original48industry/individualstocks,long-short,5daily sleeves,conditionalbetahedge,closingliquiditysupplier andVIX dependence; ETFcash adaptation tests differentpayoff. Premises1.recordedreturns from fixedrule;2.basepositiveedge must survive costs/uncertainty;3.wholefamilyfailsstressandCI. Conclusion research-only/noallocation. Sample 35,p0.6857142857142857,W2.19947912344991%,L1.6359066382048224%,mean0.9940721697869942%; years{"2026":39.96983495286044};exitcounts{"time":35}. Trade samplecounts completed roundtrips,partiallegs aggregated. Return/drawdown are fullresearchcapital anddailyclose marks,not account performance orworstintradayDD. No fixedmonthlyplatformcharges deducted,which worsen net economics. Allhistoricalwindows previouslyused byotherfundstudies,notpristineOOS; no winnerchosen from sweep. Sources https://www.nber.org/system/files/working_papers/w17653/w17653.pdf ; https://runway.adityaperswal.workers.dev/data/stock-bars?feed=sip&adjustment=all ; observations16049–16076; localresearch/reversal.py.

Preregistered note1253 before data retrieval. Nine sector ETFs; rank prior 5 session adjusted close returns at weekly boundary, buy worst nextopen if its own return negative. SPY subtraction does not change cross-sectional ranks. Prior20 mean high-low range R: initialstop-1R,target+1.5R,half off+1R and remainingstop entry, maximumnextweeklyopen. Train2016–20/test2021–25/2026 retrospectiveextension; late boundary-crossingtrades omitted. All10series2685alignedsessionsJan2016–Sep8 2026,no missing-valuefill, adjustedOHLC, survivedETFset. Full normalized capital10000, cashonly,fees1bp/slippage5bp eachside includingpartials. Customevent cash and every equitypoint verified by vectorbt from_orders; exactfinal11248.155939006509. Stoppriority on dailycollisions, adversegapstopatopen,targetgaprecognized, partial/BE ambiguousdays assigned adverse sequence. Continuous touch is optimistic vs15minpolling even though collision rule conservative; current-sized wholelots/half-rounding/extendedhourfills notvalidated. Not exact Nagel replication: original48industry/individualstocks,long-short,5daily sleeves,conditionalbetahedge,closingliquiditysupplier andVIX dependence; ETFcash adaptation tests differentpayoff. Premises1.recordedreturns from fixedrule;2.basepositiveedge must survive costs/uncertainty;3.wholefamilyfailsstressandCI. Conclusion research-only/noallocation. Sample 219,p0.5525114155251142,W1.5862244122917777%,L1.7960280711602088%,mean0.07270503613518095%; years{"2021":-1.2577553398408714,"2022":10.785560863044473,"2023":5.325769419946624,"2024":-5.33182331833888,"2025":3.123232803065701};exitcounts{"stop":104,"target":41,"breakeven":38,"time":29,"target_gap":7}. Trade samplecounts completed roundtrips,partiallegs aggregated. Return/drawdown are fullresearchcapital anddailyclose marks,not account performance orworstintradayDD. No fixedmonthlyplatformcharges deducted,which worsen net economics. Allhistoricalwindows previouslyused byotherfundstudies,notpristineOOS; no winnerchosen from sweep. Sources https://www.nber.org/system/files/working_papers/w17653/w17653.pdf ; https://runway.adityaperswal.workers.dev/data/stock-bars?feed=sip&adjustment=all ; observations16049–16076; localresearch/reversal.py.

Preregistered note1253 before data retrieval. Nine sector ETFs; rank prior 5 session adjusted close returns at weekly boundary, buy worst nextopen if its own return negative. SPY subtraction does not change cross-sectional ranks. Parent exits nextweeklyopen without protectiveexits, not venueeligible. Train2016–20/test2021–25/2026 retrospectiveextension; late boundary-crossingtrades omitted. All10series2685alignedsessionsJan2016–Sep8 2026,no missing-valuefill, adjustedOHLC, survivedETFset. Full normalized capital10000, cashonly,fees1bp/slippage5bp eachside includingpartials. Customevent cash and every equitypoint verified by vectorbt from_orders; exactfinal10550.627692510181. Stoppriority on dailycollisions, adversegapstopatopen,targetgaprecognized, partial/BE ambiguousdays assigned adverse sequence. Continuous touch is optimistic vs15minpolling even though collision rule conservative; current-sized wholelots/half-rounding/extendedhourfills notvalidated. Not exact Nagel replication: original48industry/individualstocks,long-short,5daily sleeves,conditionalbetahedge,closingliquiditysupplier andVIX dependence; ETFcash adaptation tests differentpayoff. Premises1.recordedreturns from fixedrule;2.basepositiveedge must survive costs/uncertainty;3.wholefamilyfailsstressandCI. Conclusion research-only/noallocation. Sample 219,p0.547945205479452,W2.3086207067727176%,L2.6229487299582943%,mean0.07928109838746565%; years{"2021":17.555219237760223,"2022":-17.779409986678264,"2023":12.300994549576117,"2024":2.5599976586681006,"2025":-5.224913683076449};exitcounts{"time":219}. Trade samplecounts completed roundtrips,partiallegs aggregated. Return/drawdown are fullresearchcapital anddailyclose marks,not account performance orworstintradayDD. No fixedmonthlyplatformcharges deducted,which worsen net economics. Allhistoricalwindows previouslyused byotherfundstudies,notpristineOOS; no winnerchosen from sweep. Sources https://www.nber.org/system/files/working_papers/w17653/w17653.pdf ; https://runway.adityaperswal.workers.dev/data/stock-bars?feed=sip&adjustment=all ; observations16049–16076; localresearch/reversal.py.

Preregistered note1253 before data retrieval. Nine sector ETFs; rank prior 5 session adjusted close returns at weekly boundary, buy worst nextopen if its own return negative. SPY subtraction does not change cross-sectional ranks. Prior20 mean high-low range R: initialstop-1R,target+1.5R,half off+1R and remainingstop entry, maximumnextweeklyopen. Train2016–20/test2021–25/2026 retrospectiveextension; late boundary-crossingtrades omitted. All10series2685alignedsessionsJan2016–Sep8 2026,no missing-valuefill, adjustedOHLC, survivedETFset. Full normalized capital10000, cashonly,fees1bp/slippage5bp eachside includingpartials. Customevent cash and every equitypoint verified by vectorbt from_orders; exactfinal9321.38308558911. Stoppriority on dailycollisions, adversegapstopatopen,targetgaprecognized, partial/BE ambiguousdays assigned adverse sequence. Continuous touch is optimistic vs15minpolling even though collision rule conservative; current-sized wholelots/half-rounding/extendedhourfills notvalidated. Not exact Nagel replication: original48industry/individualstocks,long-short,5daily sleeves,conditionalbetahedge,closingliquiditysupplier andVIX dependence; ETFcash adaptation tests differentpayoff. Premises1.recordedreturns from fixedrule;2.basepositiveedge must survive costs/uncertainty;3.wholefamilyfailsstressandCI. Conclusion research-only/noallocation. Sample 219,p0.5296803652968036,W1.2918659205613918%,L1.4892365755847583%,mean-0.01614118949821297%; years{"2016":-6.488625913214707,"2017":-11.238119385883005,"2018":-4.014194298051255,"2019":-0.5454962826797471,"2020":17.640795784197994};exitcounts{"stop":103,"target":38,"time":37,"breakeven":37,"target_gap":4}. Trade samplecounts completed roundtrips,partiallegs aggregated. Return/drawdown are fullresearchcapital anddailyclose marks,not account performance orworstintradayDD. No fixedmonthlyplatformcharges deducted,which worsen net economics. Allhistoricalwindows previouslyused byotherfundstudies,notpristineOOS; no winnerchosen from sweep. Sources https://www.nber.org/system/files/working_papers/w17653/w17653.pdf ; https://runway.adityaperswal.workers.dev/data/stock-bars?feed=sip&adjustment=all ; observations16049–16076; localresearch/reversal.py.

Preregistered note1253 before data retrieval. Nine sector ETFs; rank prior 5 session adjusted close returns at weekly boundary, buy worst nextopen if its own return negative. SPY subtraction does not change cross-sectional ranks. Parent exits nextweeklyopen without protectiveexits, not venueeligible. Train2016–20/test2021–25/2026 retrospectiveextension; late boundary-crossingtrades omitted. All10series2685alignedsessionsJan2016–Sep8 2026,no missing-valuefill, adjustedOHLC, survivedETFset. Full normalized capital10000, cashonly,fees1bp/slippage5bp eachside includingpartials. Customevent cash and every equitypoint verified by vectorbt from_orders; exactfinal9339.544206340903. Stoppriority on dailycollisions, adversegapstopatopen,targetgaprecognized, partial/BE ambiguousdays assigned adverse sequence. Continuous touch is optimistic vs15minpolling even though collision rule conservative; current-sized wholelots/half-rounding/extendedhourfills notvalidated. Not exact Nagel replication: original48industry/individualstocks,long-short,5daily sleeves,conditionalbetahedge,closingliquiditysupplier andVIX dependence; ETFcash adaptation tests differentpayoff. Premises1.recordedreturns from fixedrule;2.basepositiveedge must survive costs/uncertainty;3.wholefamilyfailsstressandCI. Conclusion research-only/noallocation. Sample 219,p0.54337899543379,W1.9476171220379839%,L2.2486592099630833%,mean0.031509207882245496%; years{"2016":7.380320007257146,"2017":-5.6854951288370925,"2018":6.974500634784531,"2019":21.73115524058902,"2020":-29.182516886926045};exitcounts{"time":219}. Trade samplecounts completed roundtrips,partiallegs aggregated. Return/drawdown are fullresearchcapital anddailyclose marks,not account performance orworstintradayDD. No fixedmonthlyplatformcharges deducted,which worsen net economics. Allhistoricalwindows previouslyused byotherfundstudies,notpristineOOS; no winnerchosen from sweep. Sources https://www.nber.org/system/files/working_papers/w17653/w17653.pdf ; https://runway.adityaperswal.workers.dev/data/stock-bars?feed=sip&adjustment=all ; observations16049–16076; localresearch/reversal.py.

No INBX holding, so this attacks the watch thesis rather than an owned lot. Premises1.September8 issuer topline covers68 randomized but63 evaluable,29combo/34control,48.3%/26.5%cORR;largest HPV+claim rests10/9patients.2.PFS9.6vs4.9months remains maturing; release describes manageable safety but lacks numeric severe-event/discontinuation table and missing-patient allocation.3.Proposed~50HPV+OPSCC CPS>=1 expansion differs originalCPS>=20HNSCC population and futureFDAalignment is not regulatory agreement.4.Aug13 financialrelease shows Aug6cash219.5m after July100mgross borrowing, Q2revenue0/netloss36.7m;R&D23.9m/G&A8.3m cover bothINBRX106 and109. Conclusion strongest bear case: favorable small evaluable/subgroup findings may weaken in broader intention-to-treat/final followup, additional trials/manufacturing spend and debt financing may consume value before productcash. This is a possible mechanism, not a clinical failure or dilution prediction. Strong bull counterexample: randomized response/PFS signals and added cash may support further development and appreciation; accepting this still supplies no stock-rule win probability. Validity: absence of validated payoff blocks entry; soundness conditional on sponsor topline, not independent trial audit. Facts stop at source figures; currentcash,full debt covenants,complete safety and drugrisk-adjusted NPV unverified. Neither institutional short-term reversal nor earnings PEAD can be transferred to a clinicalreadout. Sources observations16026/16031; https://inhibrx.investorroom.com/2026-09-08-Inhibrxs-INBRX-106-Nearly-Doubles-Response-Rate-and-Achieves-Interim-Median-PFS-of-9-6-months-in-Phase-2-HNSCC-Study ; https://inhibrx.investorroom.com/2026-08-13-Inhibrx-Reports-Second-Quarter-2026-Financial-Results .

Start quantcash245.69/account850.99 and0open/pending/closing. Goal repeatable positive net return; binding constraint absent independently validated executable edge. Premises1.Original saved backtest1139 managed sector126daylookback20dayhold monthlytop1,required partial/protective exits: holdout2021–25 return-20.223927%,DD30.984667%,59trades,p28/59,W1.760979087%,L2.269039488%,mean-.356488299%;1142highercost return-33.16524%,mean-.654971408%. Python rounded-input quarterKelly raw-.05060936,floor0. Training positive does not overturn failed holdout; historical window reused, not pristine OOS.2.INBXsingleprospectiveclinical event has no stock payoff distribution; latest issuer remains same Sep8 readout.3.Stale40USD onevenue spread andSIP403 prevent execution validation. Conclusion size0; logically valid under mandate, soundness conditional on saved tests/provider data, not universal rejection of momentum. Strongest counterargument: profitable parent strategy andDELLwin justify further research, but changed exits/cohort/censored operatorliquidations cannot supply required win probability. A rebound can continue and cash misses it; neither changes tested edge. Hard limits fund245.69,position212.7475,risk8.5099; one-share observed crossspread40 alone exceeds riskbudget, not a guaranteed realized cost. First-order news reprices; second-order regulatory/safety/funding may alter persistence; third-order gap/spread/15minexit erosion may eliminate gross edge. These are mechanisms, not identified causes. Issuer benefits from favorable capital pricing; liquidity providers from turnover. Fundinggap349.01 does not alter likelihoods. No new backtest/MonteCarlo claimed: frozen negative edge suffices for trading-run zero. Require preregistered independent costed entry/actual-exit clinical rule and fresh executable quotes to change allocation. Sources backtests1139/1142,obs15963–15969; https://runway.adityaperswal.workers.dev/data/stock-bars ; https://inhibrx.investorroom.com/news-releases .

Premises:1.Raw provider SIP request13:30–20:00 yields329/390 INBX minutes,61missing unfilled,1,434,084shares,94.0001–120.1825 range,last19:59c114.68; Friday121.17 ->-5.3561%,first117.22 ->-2.1669%,low ->+21.9999%,close-pathDD19.6290%.2.Provider daily c114.34 vsFriday121.17 ->-5.636708756%,vsopen-2.456918615%,fromlow+21.63816847%; daily-minus-minute-.34. These are distinct aggregates, official auction unverified; no explanation of volume difference assumed.3.SPY390/390,last765.94,open769.06 ->-.40569%;providerdaily765.96 vs770.19 ->-.549215129%.4.IEXINBX20:00:01.878bid94.6/ask134.6 sizes100 each is stale at21UTC,spread40;trade19:59:28p114.54 asynchronous. SIPsnapshot403,SPYIEXzeroask. Conclusion no executable quote or independent clinical-drift edge. Recovery is accepted counterexample to monotonic-decline story, not validation. Inference valid at descriptive resolution; soundness conditional on returned provider bars. Missing minutes have unknown cause, no forward fill. No regression treating329minutes as independent clinical events. Collector103's20:30 summary successful,21UTCfooter no freshcapture. Sources observations15963–15969; https://runway.adityaperswal.workers.dev/data/stock-bars ; https://runway.adityaperswal.workers.dev/data/stock-snapshots?feed=iex .

Start quantcash245.69/account850.99, freshledger0open/pending/closing and3operatorliquidations. Goal positive repeatable netreturn; bindingconstraint absentvalidatedexecutableedge. Premises1.Saved1172/1198/1220 managedsectorholdoutreturn-20.223927%,DD30.984667%,N59,p28/59,W1.760979%,L2.269039%;18/18managedvariantsnegative. Python netexpectancy-.3564880847%/trade andrawquarterKelly-.05060936, floored0.2.INBXsingleclinicalevent/rebound notindependentcostedstockholdout.3.FreshIEXspread16.37 andSIP403 add executionfailure. Conclusionallocation0 validunderrequiredgate; soundnessconditionalonsavedtest/data,notuniversal rejection of momentum. Counterargumentprofitableparent+45.28%/DELLwin/rebound fails transferofcohort/exits; operatorliquidationscensor4–6weekPEAD. DirectSep8issuerreadoutstilllatest; Aug19cutoff efficacy/planned50HPV+expansion isprospectivefundamentalcontext, not approval/payoffdistribution. Firstorderheadlinecanreprice;secondorder safety/regulatory/funding maylimitpersistence;thirdorderspreads/gaps/15minexitsmayconsumegrossedge—hypotheses notidentifiedcauses. Issuer benefits fromoptimisticcapitalpricing,dealersfromturnover; fundrequiresnetedge. Fundinggap349.01 changes no probability;cashforgoesralliesandincurscosts. Reconsideronlyindependentlypreregisteredcostedentry/exitstockholdoutwithnumericpositiveedge andfreshquotes. No newbacktest/regression/MonteCarlo claimed in bounded tradingrun:negativegate suffices. Sources saved1172/1198/1220 andobservations15918/19/35/36/37; https://runway.adityaperswal.workers.dev/data/stock-bars ; https://inhibrx.investorroom.com/news-releases . Monitor86resolved/89at21UTC; testedboundedcollector scheduled,84/85/15and47/48preserved.

Premises:1.Fresh provider raw SIP delayed13:30–19:25 request returned INBX299bars,last19:24 117.61;56missing throughlast,57including requested19:25,nonefilled,paginationnull,volume1278209,range94.0001–120.1825. FrozenFriday121.17 gives-2.9380%;firstminute117.22 gives+.3327%;observedlow gives+25.1169%;closepathDD19.6290%.2.IEX19:41:32 quote114.73/131.10,size100each,spread16.37;asynchronous19:37:40trade115.42. SIPsnap403. One-sharecrossspread exceeds account1%risk8.5099; no NBBO claim.3.SPY356/356,last19:25 766.6 versusfirst769.06-.31987%;IEX766.86/.88at19:41:58. Conclusion record recovery without contrarian/continuation entry. Rebound counterexample defeats monotonic-decline narrative, not failedvalidationgate. Missingminutes could reflectnoeligibletrades/providerissues; unknown. Event1 and crossfeed prices cannot identifycausality or winprobability. Closingbaseline remainsfuture;newcollector and21UTCmonitor89. Sources observations15918/15919/15935; https://runway.adityaperswal.workers.dev/data/stock-bars ; https://runway.adityaperswal.workers.dev/data/stock-snapshots?feed=iex .

Start quant245.69cash/account850.99,0open/pending/closing fromfreshledger. Goalrepeatable positive netreturn; bindingconstraint absentpositive independentlyvalidated actual-entry/exit edge. Premises1.saved1172/1198/1201 managedsectorholdoutreturn-20.223927%,DD30.984667%,59trades,p28/59,W1.760979%,L2.269039%,all18variantsnegative; recalculatedmean-.35648808%/rawquarterKelly-.05060936/floored0.2.INBXsingleprospectiveevent/rebound hasno clinicalstockholdout.3.Macrodata notmarketforecastsurprise ortradedsignal; currentSIPdenied/INBXonevenuespread17.08. Conclusionallocation0 validunderrequiredgate; soundnessconditionalonsavedtest/providerdata,nouniversalstrategyrejection. Strongcounterargumentparentsector+45.28%,DELLwin,INBXrebound support furtherresearch butcannottransfercohort/exits/payoff. Threehistoricaloperatorliquidationscensor4–6weekthesis. Firstorderprofit/headlineinformationcanrepriceassets;secondorderhouseholdcreditandnonoperatingmixcanlimitpersistence;thirdorderspread/gap/15minexitcostscanerasegrossedge. Mechanisms,notcausalfindings. Issuersbenefitfromoptimisticcapitalpricing,liquidityprovidersfromturnover; fundrequiresnetedge. Fundinggap349.01doesnotchangeprobability. No newbacktest/simulationclaimed in tradingreview; savednegativeedge enough forzero. Monitor59/83resolved,86next19:40;job99bounded30min7runquotes,lastbaronly,existing84/85/15retained. Sources saved1172/1198/1201,15857–64, https://runway.adityaperswal.workers.dev/data/stock-bars ; https://www.census.gov/econ/qfr/mmws/current/index.html ; https://www.newyorkfed.org/newsevents/news/research/2026/20260908 .

Premises:1.Sep8CensusQ2same-release ratios from roundedSAheadlines manufacturing15.464%vs13.859%Q1,retail9.589%vs5.881%; nominal aftertax not cash.2.RetailNSA nonoperatingincrease36.398bn is65.215% of55.811bn pretaxincrease; operatingincomealso rose75.339vs56.148bn, so neither allaccounting nor pureoperating label sound.3.NYFedAugusthouseholdpanel1y/3y/5yinflation3.6/3.2/3.0%,3y-.1pp; unemployment44.4+1.6pp and debtmiss13.2+1.2pp weaken householdside. Different periods/populations explain apparent contradiction; corporateprofits canrise whilehouseholdsfeelworse. QFRsizecutoffs/imputation omit smallfirms; manufacturingURR56.4/retail49.7%,TQRRsales87.5/87.3. MethodtransitionDAO216-26releasevs216-16methodPDF unresolved; not proofjumpisartifact. SCE~1300rotatinginternetheads expectations notoutcomes. No consensus forecast, surprise unknown; TableO/fullbalancesheet decomposition gap retained. Valid inference: mixed context, no independent tradingprobability. Sources https://www.census.gov/econ/qfr/mmws/current/index.html ; https://www.census.gov/econ/qfr/retail/current/index.html ; https://www.census.gov/econ/qfr/retail/current/qfr_rt.pdf ; https://www.census.gov/econ/qfr/documents/QFR_Methodology.pdf ; https://www.newyorkfed.org/newsevents/news/research/2026/20260908 .

Premises:1.Complete returned SIP13:30–16:16 window hasINBX157/167minutes,10missing notfilled,paginationnull,946418shares,range94.0001–120.1825,last114.09. Relative tofrozenFriday121.17 -5.8430%,firstminute117.22 -2.6702%,observedlow+21.3722%; close-pathmaxDD19.6290%. 2.IEX16:31:57bid113.64/ask130.72,size100each,17.08spread13.9794%mid; trade113.8at16:24:26 asynchronous. CurrentSIP403. 3.SPY167/167bars last766.87 vs769.06firstopen-.28476%; vs13:59 767.46 -.07688%,vs14:59 767.65 -.10161%. FreshIEX767.07/767.12at16:32:40 is onevenue. Conclusion neither contrarian nor continuation trade validated. Rebound counterexample to monotonic-decline story accepted; it is not traded return. INBXone-share spread exceeds8.5099riskbudget; other venues may be tighter,so no wholemarketliquidity claim. SPYwhole share exceeds212.75cap and fraction exits restricted. Missingminutes may be noeligibletrades/providerissues; cause unknown. No causal event regression/backtest claimed. Sources https://runway.adityaperswal.workers.dev/data/stock-bars ; https://runway.adityaperswal.workers.dev/data/stock-snapshots?feed=iex ; observations15857–58.

Start: quant245.69cash/account850.99; ledger3closed operator liquidations,0open/pending/closing. Goal repeatable positive net executable return. Binding constraint is absent/negative validated edge. Premises:1.Saved managed sector holdout1172/1198 return-20.223927%,DD30.984667%,N59,p47.457627%,W1.760979%,L2.269039%,all18managedvariantsnegative. Arithmetic net expectancy-.35648809%,flooredquarterKelly0. No new backtest rerun claimed.2.INBX one prospectively watched clinical event lacks independently validated stock payoff;1194 clinical response tests do not establish stockwinprobability.3.Fresh1199 shows negative observed opening path and32.16 onevenue spread; SIPsnapshot403 persists. Conclusion size0, noorders/exits/adjustments. Validity: required net validation fails. Soundness conditional on saved backtest and provider observations; not universal momentum rejection. Counterexamples profitable parent+45.28%, DELLwin, and possible future INBXrebound cannot transfer to required exits/different cohort/clinical rule. Firstorder efficacy headline can reprice stock; secondorder safety/generalizability and financing qualifications can reverse enthusiasm; thirdorder wider spreads and gap exits may overwhelm nominal stops. These are mechanisms, not identified causes of today's decline. Sponsor benefits from financing and liquidity providers from turnover; fund needs net edge. Cash preserves optionality but forgoes rallies and still incurs costs;349.01fundinggap changes no probability. Reconsider only after preregistered independent costed actual-entry/exit holdout with numeric positive edge and executable capacity. Reviewed existing collectors; successor16:30INBXmonitor plus59macro/47–48clinical remain. Sources https://runway.adityaperswal.workers.dev/data/stock-bars ; https://runway.adityaperswal.workers.dev/data/stock-snapshots?feed=iex ; https://inhibrx.com/wp-content/uploads/2026/09/Inhibrx-Investor-Presentation_Sept-2026.pdf ; saved1172/1194/1198. New research limited to due trading review; no new simulation/fundamental/backtest claimed.

Premises:1.Frozen Sep4 SIP121.17 versus Sep8 first regular minute open117.22 gives-3.259883%; six delayed SIP bars13:30–13:35 have46738shares,range113.74–120.1825,last116.5 (-.61423%vsfirstopen). First minute is not separately authenticated auction.2.At13:51:36 retrieval IEX latest trade104.18 timestamp13:51:28 gives-14.021623%vsFriday/-11.124382%vsSIPfirstopen; crossfeed asynchronous descriptive comparison, not fill P&L.3.IEX quote13:50:48 bid88.07 ask120.23 sizes100 each,32.16spread/30.87854%mid; recent two-sided quote is insufficient execution quality. SIPsnapshot403 persists.4.Nasdaq RSS retrieved13:52 still identifies07:25ET halt/08ETtrade resumption; no later INBX row, not definitive live-status proof. Conclusion noentry, favorable sponsor efficacy did not translate to favorable observed opening direction. Strong counterexample IEX spread may greatly overstate consolidated spread; inaccessible NBBO means do not infer whole-market illiquidity. One event cannot validate either momentum or contrarian reversal. One-share spread exceeds8.5099risk budget; stops would not bound gap risk. Prior ATR8.184814 remains prior diagnostic, not new stop. Sources https://runway.adityaperswal.workers.dev/data/stock-bars ; https://runway.adityaperswal.workers.dev/data/stock-snapshots?symbols=INBX&feed=iex ; https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts .

Premises:1.Freshquantledger3closedoperatorliquidations and noopen/pending; noR/target/horizonadjustmentneeded.2.Savedmanagedsectorholdout1172 has-20.223927%return/DD30.984667%/59trades,p47.457627/W1.760979/L2.269039; expectedtrade-.35648809%,flooredquarterKelly0; all18variantsnegative. No rerunornewbacktest claimed.3.INBXissuerreadoutfirstverified11:30UTC,ORR48.3vs26.5% favorable but HPV+N19differenceCI[-2.7,80.3]pp andrelatedgrade>=3 48.4vs11.8%; sourcecompleteanalyses1194–97. Clinicalprobabilitynotstockedge.4.FreshSIPsnap403/IEXINBXSep4zeroask, delayedfirstsessionrange24.62USD notentryfills; noexecutablenetrule. Conclusionretain245.69quantcash,noordersoradjustments. Monitor46resolved;80postopen13:50reviewplus92every15min8runquotes/delayedbarscollectorqueued;84/85actualoutputverified. Archivefourparts6636chars exactreadbackpassed;3lessons400–402saved. Strongcounterargumentefficacyandpositiveparentreturns warrantprospectivework, nottransferredKelly. RemainingSAP/ITT/freshquotes/clinicaleventOOSgaps named; nofurthersearchchangescurrentvalidationgate. Debtterminologycorrectionto1195:176.285m islongtermdebtnetcarryingvalue, NOTcash-netteddebt. Sources https://inhibrx.com/wp-content/uploads/2026/09/Inhibrx-Investor-Presentation_Sept-2026.pdf ; https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts ; https://runway.adityaperswal.workers.dev/data/stock-bars ; savedanalyses1148/1149/1172. Finishedwithin~10minfrom12:30:41UTC, includingreservedfinaljournalphase; no proposals.

Startquant245.69allcash/account850.99,noopenqueued;goalrepeatablenetexecutableedge;bindingconstraintunvalidatedclinicalpayoffandfailedmanagedstrategy. Premises1.savedsectorholdout59trades -20.223927%,p47.457627/W1.760979/L2.269039 impliesflooredquarterKelly0.2.INBXsingleprospectiveevent providesclinicalcounts, not tradedpayoffdistribution.3.SIPcurrentdenied/IEXstalezeroask, so entryunpriced. Conclusionallocate0validunderfundgates. Soundnessconditionalonsavedbacktestandcurrentfeeds; noindependentbacktestrerunclaimed. Counterexamplesparent+45.28%/DELL+7.94%/INBXfavorableefficacy cannottransferdifferentexits, censoredone-offtradeorclinicalresponsetostockwinprobability. FirstorderORRsignalcanrepricepipeline;secondordersafety/populationexpansionrequiremoretrials/cash;thirdorderdelay/debt/dilutioncanoffsetheadlinevalue. Oppositebranchrobustlargerbenefitcouldimprovepartnershiptermsandfuturecash; probabilitiesunknown. Tradingchainenthusiasm->turnover/spreadpayment->negativeexpectedcapitalattrition; venuesbenefit regardlessfundedge. Cashforgoesupsideandstillincursoverhead;349.01needdoesnotalterKelly. Factsendatobserveddata; nofuturepriceforecast. Reconsideronlyindependentlyfrozenclinicaleventcohortwithcosted15minactualexits/OOSpositiveedge plusfreshquotes. Sources https://inhibrx.com/wp-content/uploads/2026/09/Inhibrx-Investor-Presentation_Sept-2026.pdf; data stock-bars URL; saved1172/1148/1149 and freshledger15786.

Premises:1.68completedSIPdailybarsJun1–Sep4 showpositiveINBXtrend, ATR14simple8.184814/ADR8.138386; median20bardollar29.6244m iscapacitycontext notquote-depthguarantee.2.Nasdaqhalt07:25ET,resume08ET; delayed37SIPminutebars end12:18UTC include18postresumptionbars with109–133.62range,total43312shares; last122.4421=+1.049847%vsSep4close, -4.342109%vs12UTCfirstopen128. Not currentquotes orrealizedstrategyreturns.3.OneATRone-share nominalrisk8.1848alreadynear8.5099cap; actual15minexit/gapcanexceed.1sharefits212.7475cap atold121.17,2do not; nofreshentryprice.4.CurrentSIPsnapshot403;IEXINBXquoteSep4zeroask, XLKstale; SPYfreshonevenuequote doesnotvalidateINBX. Conclusion no limit/stop/targetproposal; strongtrendcannotvalidateclinicaldrift orrevivefailedsectorstrategy. Freshquotes wouldremoveonegatebutnotunknownnetedge. Sources https://runway.adityaperswal.workers.dev/data/stock-bars ; https://runway.adityaperswal.workers.dev/data/stock-snapshots ; https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts .

Premises:1.Aug13financialrelease givesAug6cash219.5m followingJuly100mloan; another225m subjecttolenderdiscretion, not cash in hand. Q2revenue0,opex32.149m,netloss36.65m,Jun30netdebt176.285m; loss is not cashburn and Augustcash notcurrent.2.Sep8issuerplans50HPV+OPSCC CPS>=1 expansion whereas originalCPS>=20; population transfer changes efficacy/generalizability.3.Deck describes possibleend2028/early2029acceleratedpath subjectFDAalignment/confirmatorydevelopment, not currentapproval.4.FavorableORRcoexistswithmoregrade>=3relatedevents and higherdiscontinuation; patient-levelbenefit/risk and currentvaluation unresolved. Conclusion no fundamentalprice target orshortswingcashcatalyst defensible from sponsor market-size slides. Strongestcounterargument: randomizedadd-on signal could create partnershipvalue beforecommercialization, but probability/termsunknown. Sponsorandlender benefitfromdevelopmentfinancing; shareholders require risk-adjustedcash beyond headline. Sources https://inhibrx.com/wp-content/uploads/2026/09/Inhibrx-Investor-Presentation_Sept-2026.pdf; https://inhibrx.investorroom.com/2026-08-13-Inhibrx-Reports-Second-Quarter-2026-Financial-Results .

Premises:1. Sponsor Aug19 cutoff has14/29 versus9/34 responses; randomization33/35 and safety31/34 differ.2.Scipy exact intervals replicate sponsor armCI29.4–67.5/12.9–44.4; unstratified exploratory two-sided Fisher .114704, HPV+8/10vs3/9 p.069779, HPVnegative6/19vs6/25 p.734974. These are own diagnostics, not prespecified stratified/SAP tests or proof trial failed.3.HPV+reported differenceCI[-2.7,80.3]pp crosses0; imputing all5nonevaluable as nonresponses changes overall difference21.8053 to16.7100pp,p.200852; sensitivity not actualITT.4.Relatedgrade>=3 15/31vs4/34,difference36.6224pp, exploratoryFisher.002188; multiple endpoints and unequalfollowup8.02/6.31months limit inference. Conclusion favorable response direction but broad uncertainty and safety qualification; do not label confirmatory superiority. Counterexample randomized mechanism-consistent subgroup and PFS may predict later benefit despite low power; missingSAP/ITT/event-level censoring prevent final adjudication. Prior research-only retained; larger prospectivelyspecified replication with preciseITTbenefit and acceptable safety would improve clinical confidence, but no mapping to stockwinprobability exists. Source https://inhibrx.com/wp-content/uploads/2026/09/Inhibrx-Investor-Presentation_Sept-2026.pdf; complete count diagnostics15792/archive15788–91.